Shaperon (XKRX:378800) FCF Margin % : -19,619.73% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Shaperon FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Shaperon's Free Cash Flow for the three months ended in Jun. 2024 was ₩-3,473.67 Mil. Shaperon's Revenue for the three months ended in Jun. 2024 was ₩17.71 Mil. Therefore, Shaperon's FCF Margin % for the quarter that ended in Jun. 2024 was -19,619.73%.

As of today, Shaperon's current FCF Yield % is -13.99%.

The historical rank and industry rank for Shaperon's FCF Margin % or its related term are showing as below:

XKRX:378800' s FCF Margin % Range Over the Past 10 Years
Min: -17637.73 Med: -1434.74 Max: -406.95
Current: -17637.73

During the past 5 years, the highest FCF Margin % of Shaperon was -406.95%. The lowest was -17637.73%. And the median was -1434.74%.

XKRX:378800's FCF Margin % is ranked worse than
93.14% of 1049 companies
in the Biotechnology industry
Industry Median: -143.16 vs XKRX:378800: -17637.73

Shaperon FCF Margin % Historical Data

The historical data trend for Shaperon's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shaperon FCF Margin % Chart

Shaperon Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-1,434.74

-406.95

-6,941.64

Shaperon Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial						-2,193.25	-	-6,338.54	-	-19,619.73

Competitive Comparison of Shaperon's FCF Margin %

For the Biotechnology subindustry, Shaperon's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shaperon's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shaperon's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Shaperon's FCF Margin % falls into.

Shaperon FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Shaperon's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-14941.953	/	215.251
	=	-6,941.64 %

Shaperon's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-3473.674	/	17.705
	=	-19,619.73 %

Shaperon FCF Margin % Related Terms

Thank you for viewing the detailed overview of Shaperon's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shaperon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shaperon Inc (XKRX:378800) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gangnam Ace Tower G9, Suie 218 & 606, 174-10 Jagok-ro, Gangnam-gu, Seoul, KOR, 06373

Website

http://www.shaperon.com

Shaperon Inc is a developer of innovative inflammasome inhibitors and nanobody therapeutics intended to develop novel treatments for various chronic inflammatory diseases, including atopic dermatitis, systemic inflammatory response syndrome, neuroinflammatory diseases, and chronic inflammation. It offers a range of drug candidates, including a gel-type atopic dermatitis drug for use in the treatment of systemic inflammatory response syndrome, neuroinflammatory diseases and for treating chronic inflammation. The company also provides immunotherapeutic products and a single-domain neutralizing antibody, enabling clients to improve patient's quality of life by developing safe and efficacious drugs and immunotherapies.

Shaperon Headlines

No Headlines